Investigating the Potential of Adenosine Receptor Blockade for the Treatment of Breast Cancer

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

S Dushyanthen, ZL Teo, F Caramia, P Savas, CP Mintoff, B Virassamy, MA Henderson, SJ Luen, M Mansour, MH Kershaw, JA Trapani, PJ Neeson, R Salgado, GA McArthur, JM Balko, PA Beavis, PK Darcy, S Loi

2017-12-01

The presence of tumor-infiltrating lymphocytes in triple-negative breast cancers is correlated with improved outcomes. Ras/MAPK pa..

CMTM6 maintains the expression of PD-L1 and regulates anti-Tumour immunity

ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, EYN Lam, MA Henderson, CC Bell, S Stolzenburg, O Gilan, S Bloor, T Noori, DW Morgens, MC Bassik, PJ Neeson, A Behren, PK Darcy, SJ Dawson, I Voskoboinik

2017-09-07

Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillanc..

Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting

CY Slaney, B Von Scheidt, AJ Davenport, PA Beavis, JA Westwood, S Mardiana, DC Tscharke, S Ellis, HM Prince, JA Trapani, RW Johnstone, MJ Smyth, MW Teng, A Ali, Z Yu, SA Rosenberg, NP Restifo, P Neeson, PK Darcy, MH Kershaw

2017-05-15

Purpose: While adoptive transfer of T cells bearing a chimeric antigen receptor (CAR) can eliminate substantial burdens of some le..

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, S Combs, DL Rimm, JM Giltnane, MV Estrada, V Sánchez, ME Sanders, RS Cook, MA Pilkinton, SA Mallal, K Wang, VA Miller, PJ Stephens, R Yelensky, FD Doimi

2016-03-15

Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuv..

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy

PA Beavis, CY Slaney, MH Kershaw, D Gyorki, PJ Neeson, PK Darcy

2016-02-01

The frontiers of cancer immunotherapy are extending in terms of both the range of cancer types that can potentially be targeted an..

CD73: A potential biomarker for anti-PD-1 therapy

PA Beavis, CY Slaney, N Milenkovski, MA Henderson, S Loi, J Stagg, MH Kershaw, PK Darcy

2015-11-02

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomi..

Relevance of tumor-infiltrating lymphocytes in breast cancer

S Dushyanthen, PA Beavis, P Savas, ZL Teo, C Zhou, M Mansour, PK Darcy, S Loi

2015-08-24

While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recent studies have demonstrated ev..